迪安诊断技术集团股份有限公司独立董事候选人声明 声明人邓泽林，作为迪安诊断技术集团股份有限公司第五届董事会独立董 事候选人，现公开声明和保证，本人与该公司之间不存在任何影响本人独立性 的关系，且符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易 所业务规则对独立董事候选人任职资格及独立性的要求，具体声明如下： 一、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担 任公司董事的情形。 √ 是 □ 否 如否，请详细说明：______________________________ 如否，请详细说明：______________________________ 三、本人符合该公司章程规定的独立董事任职条件。 √ 是 □ 否 如否，请详细说明：______________________________ 四、本人已经按照中国证监会《上市公司高级管理人员培训工作指引》的 规定取得独立董事资格证书。 □ 是 √ 否 如否，请详细说明： _邓泽林承诺积极报名参加深圳证券交易所组织的最近 一期独立董事培训，并承诺取得深圳证券交易所认可的独立董事证书 五、本人担任独立董事不会违反《中华人民共和国公务员法》的 ...

证券代码：300244 证券简称：迪安诊断 公告编号：2023-038 迪安诊断技术集团股份有限公司 迪安诊断技术集团股份有限公司 监事会 2023 年 10 月 18 日 第四届监事会第二十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2023 年 10 月 18 日上午 10 点，迪安诊断技术集团股份有限公司（以下简称 "公司"或"迪安诊断"）以通讯表决的方式召开了第四届监事会第二十一次会议。 会议通知已于 2023 年 10 月 15 日以电话、电子邮件等方式通知全体监事。会议 由公司监事会主席程秀丽女士召集和主持。本次监事会应到监事 3 名，实到监事 3 名，符合《公司法》和《公司章程》的规定，全体监事以通讯表决方式通过了 以下决议： 一、审议《关于公司监事会换届暨选举第五届监事会非职工代表监事的议 案》 鉴于公司第四届监事会任期已经届满，根据《公司法》、《公司章程》等有 关规定，监事会同意提名师玉鹏为公司第五届监事会非职工代表监事候选人，任 期自股东大会通过之日起三年。为确保公司监事会的正常运作，在新一届监事会 监事就任前，公司第 ...

鉴于公司第四届董事会任期已经届满，根据《公司法》《公司章程》等有关 规定，经公司董事会提名委员会进行资格审查，董事会同意提名陈海斌、叶小平、 俞德超、郭三汇、洪汉华、赵德康为公司第五届董事会非独立董事候选人，任期 股东大会通过之日起三年。为确保公司董事会的正常运作，在新一届董事会非独 立董事就任前，公司第四届董事会非独立董事仍将按照法律法规、规范性文件和 《公司章程》 的规定，忠实、勤勉履行董事义务和职责。 证券代码：300244 证券简称：迪安诊断 公告编号：2023-037 迪安诊断技术集团股份有限公司 第四届董事会第三十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2023 年 10 月 18 日上午 10 点，迪安诊断技术集团股份有限公司（以下简称 "公司"或"迪安诊断"）以通讯表决相的方式召开了第四届董事会第三十二次会 议。会议通知已于 2023 年 10 月 15 日以电话、电子邮件等方式通知全体董事。 会议由公司董事长陈海斌先生召集和主持。本次会议应参加表决的董事 8 人，实 际参加表决的董事 8 人，符合《公司法》《证券法》 ...

Financial Performance - The company reported a revenue of RMB 1.5 billion for the first half of 2023, representing a year-on-year increase of 15%[5]. - The net profit attributable to shareholders for the same period was RMB 300 million, up 20% compared to the previous year[5]. - The company has set a revenue guidance of RMB 3.2 billion for the full year 2023, indicating a growth target of 12%[5]. - The company's operating revenue for the reporting period was ¥6,841,865,799.52, a decrease of 36.37% compared to the same period last year[32]. - Net profit attributable to shareholders was ¥453,293,178.55, down 75.89% year-on-year[32]. - The net profit from non-recurring gains and losses was ¥332,157,986.33, reflecting an 82.32% decline compared to the previous year[32]. - Basic earnings per share decreased to ¥0.7231, down 76.11% from ¥3.0269 in the same period last year[32]. - The company reported a total of ¥40,962,300.08 in increases for employee stock ownership plans during the current period[146]. - The total unallocated profit at the end of the period reached ¥5,153,944,516.79, up from ¥4,825,647,225.44, indicating a growth of about 6.8%[148]. - The net profit attributable to the parent company for the current period was ¥453,293,178.55, a decrease of approximately 68.4% compared to ¥1,434,191,144.16 in the previous period[148]. Operational Highlights - User data showed an increase in the number of tests conducted, reaching 5 million tests in the first half of 2023, a growth of 10% year-on-year[5]. - The company operates 43 chain laboratories, covering over 90% of the population in China, and serves more than 22,000 medical institutions[37]. - The company offers over 3,300 medical testing projects, including molecular diagnostics and pathology diagnostics, with 67 domestic and international certifications[37]. - The company serves over 4,000 end customers with a product portfolio of approximately 1,000 types, integrating upstream and downstream supply chains in the medical diagnostics industry[52]. - The company has over 3,300 testing projects available through its nationwide independent laboratory network, providing timely medical diagnostic outsourcing services[52]. Strategic Initiatives - The company plans to expand its market presence by opening 10 new independent clinical laboratories (ICLs) by the end of 2023[5]. - The company is exploring potential mergers and acquisitions to enhance its service offerings and market reach[5]. - The company is actively participating in the reform of the Chinese medical system, leveraging its technological platform and cost advantages to expand market share[54]. - The company is focusing on new product development and technology research, including projects related to drug testing methods[144]. - The company aims to leverage advanced technologies such as NGS (Next-Generation Sequencing) to improve diagnostic accuracy and efficiency[5]. Financial Position - Total assets at the end of the reporting period were ¥19,780,255,773.69, a decrease of 6.06% from the end of the previous year[32]. - The total cash and cash equivalents at the end of the period amounted to ¥171,598,471.35, an increase of 14.23% from the beginning balance of ¥150,232,779.57[77]. - The company recorded a total accounts receivable of approximately $10.53 billion, with a bad debt provision of $864.52 million, representing a provision ratio of 8.21%[71]. - The company made a bad debt provision of approximately $246.29 million during the reporting period, with a write-off of $2.42 million[72]. - The company’s accounts receivable aging shows that 93.20% of the total is within one year, indicating strong short-term collection capability[75]. Challenges and Risks - The management highlighted risks related to regulatory changes and competition in the diagnostics market[4]. - The company has experienced an increase in accounts receivable, which may lead to longer settlement periods due to intensified competition and new business models[126]. - The company has implemented measures to strengthen accounts receivable management to mitigate the risk of bad debts, including establishing a tracking mechanism and enhancing credit management[126]. Government and Regulatory Matters - The company has a tax rate of 15% for the fiscal year 2023, benefiting from high-tech enterprise certification[55]. - Government grants received during the period amounted to CNY 2,404,633.67, with a remaining balance of CNY 13,869,421.57 at the end of the period[141]. - The company received government subsidies totaling ¥23,041,183.10 in the current period, compared to ¥19,507,471.42 in the previous period, indicating an increase of approximately 7.85%[193]. Miscellaneous - No cash dividends or stock bonuses will be distributed to shareholders for this fiscal year[4]. - The company has no discrepancies in net profit and net assets between international and Chinese accounting standards for the reporting period[32]. - The company has not reported any significant accounting errors affecting the beginning retained earnings, which remained at ¥4,825,647,225.44[148]. - The company has not disclosed any new product developments or market expansion strategies in the provided content[184].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 3.23 billion, a decrease of 30.48% compared to CNY 4.65 billion in the same period last year[9]. - The net profit attributable to shareholders for Q1 2023 was CNY 160 million, down 78.74% from CNY 753.71 million year-on-year[9]. - The net profit excluding non-recurring items for Q1 2023 was CNY 139 million, a decline of 81.47% compared to CNY 747.65 million in the previous year[9]. - The total comprehensive income attributable to the parent company was ¥160,273,989.61, down from ¥753,710,562.37, showing a decline of approximately 78.8%[33]. - Basic earnings per share dropped to ¥0.2557 from ¥1.2148, reflecting a decrease of about 78.9%[33]. Cash Flow - The company's cash flow from operating activities improved to -CNY 228.73 million, a 76.50% increase from -CNY 973.14 million in the same period last year[7]. - The cash flow from investment activities improved to -CNY 75.06 million, a 61.65% increase from -CNY 195.74 million year-on-year[7]. - The net cash flow from investing activities was -75,059,602.72 CNY, an improvement from -195,744,317.28 CNY in the previous year[36]. - The total cash inflow from financing activities was 189,752,063.35 CNY, down from 1,719,594,332.00 CNY in the same period last year[36]. - The company reported a net cash flow from financing activities of -301,079,035.95 CNY, compared to a positive flow of 473,419,812.78 CNY last year[36]. Assets and Liabilities - The total assets as of March 31, 2023, were CNY 21.06 billion, reflecting a slight increase of 0.50% from the end of the previous year[15]. - Current liabilities decreased to ¥7,323,507,701.78 from ¥7,747,956,631.67, representing a reduction of about 5.5%[28]. - The total liabilities increased to ¥7,323,507,701.78, compared to the previous period's liabilities of ¥7,747,956,631.67, indicating a decrease of about 5.5%[28]. - The company's total equity increased to ¥10,187,640,437.33 from ¥9,501,998,668.78, representing an increase of approximately 7.2%[51]. - The company's long-term borrowings decreased to ¥2,823,290,000.00 from ¥2,968,290,000.00, a decline of about 4.9%[51]. Investments and R&D - The long-term equity investment decreased by 47.42% to CNY 570 million due to the acquisition of a joint venture[7]. - The company invested 100 million CNY in R&D during the reporting period[42]. - The company established a new investment partnership in March 2023 with a total fund registration completion[47]. Revenue Breakdown - Revenue from diagnostic services reached 1.222 billion CNY, a year-on-year increase of 26.21% excluding COVID-related business[42]. - Revenue from self-developed products grew to 124 million CNY, marking a 51.22% increase year-on-year excluding COVID-related business[42]. - The total revenue from channel products was 1.998 billion CNY, reflecting a 9.39% year-on-year growth[42]. Other Income and Expenses - The company reported a significant increase in other income, which rose by 362.89% to CNY 21.32 million, primarily due to increased government subsidies[7]. - The sales expenses for Q1 2023 were CNY 262.26 million, down 32.75% from CNY 390 million in the previous year, attributed to the decline in revenue[7]. - The company recorded a government subsidy of 21,554,557.43 CNY during the reporting period[40]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,155[43]. - The company completed a share buyback of 1,918,600 shares, accounting for 0.31% of the total share capital, with a total transaction amount of CNY 49.99 million[25].

证券代码：300244 证券简称：迪安诊断 迪安诊断技术集团股份有限公司投资者关系活动记录表 编号：2023-002 | 投资者关系活动 | □特定对象调研 □分析师会议 | | | | | | --- | --- | --- | --- | --- | --- | | 类别 | □媒体采访 业绩说明会 | | | | | | | □新闻发布会 □路演活动 | | | | | | | □现场参观 | | | | | | | □其他（股东大会交流） | | | | | | 参与单位名称及 | 参与公司 2022 年度网上业绩说明会的投资者 | | | | | | 人员姓名 | | | | | | | 时间 | 月 2023 4 24 15:00-17:00 | 年 | | | 日 | | 地点 | 全景网"全景·路演天下"（http://rs.p5w.net） | | | | | | | （本次年度业绩说明采用网络远程的方式举行） | | | | | | 上市公司接待人 | 董事长：陈海斌 | | | | | | 员姓名 | 董事、总经理：黄柏兴 | | | | | | | 财务负责人：姚震 | | | | ...

股票代码：300244 股票简称：迪安诊断 公告编号：2023-020 迪安诊断技术集团股份有限公司 关于举行 2022 年年度报告业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2023 年 4 月 19 日 出席本次说明会的人员有：董事长陈海斌、总经理黄柏兴、财务负责人姚震、 独立董事丁国其、董事会秘书陶钧。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年年度业绩说明会 提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 24 日（周一）15:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进入 问题征集专题页面。公司将在 2022 年年度业绩说明会上，对投资者普遍关注的 问题进行回答。 欢迎广大投资者积极参与本次网上说明会。 （问题征集专题页面二维码） 特此公告。 迪安诊断技术集团股份有限公司 董事会 迪安诊断技术集团股份有限公司（以下简称"公司"或"迪安诊断"）定于 2023 年 4 月 24 日（周一）15:00-17:00 在全景网举办 2022 年年度报 ...

Financial Performance - In 2022, the company achieved a revenue of 20.282 billion yuan, representing a year-on-year growth of 55.03%[24] - The net profit attributable to shareholders reached 1.434 billion yuan, an increase of 23.33% compared to the previous year[24] - The total revenue from diagnostic services was 12.674 billion yuan, with a significant growth of 91.46% year-on-year; revenue from COVID-19 nucleic acid testing was 8.039 billion yuan[25] - Excluding COVID-19 nucleic acid testing, the revenue from diagnostic services was 4.635 billion yuan, reflecting a growth of 15.47% year-on-year[25] - The company's total revenue reached 9.398 billion yuan, representing a year-on-year growth of 28.37%[58] - Revenue from self-produced products was 1.533 billion yuan, a significant increase of 132.78% compared to the previous year[58] - Revenue from channel products amounted to 7.865 billion yuan, reflecting an 18.05% year-on-year growth[58] - The total revenue for the company in 2022 was ¥20,282,469,258.28, representing a year-on-year increase of 55.03% from ¥13,082,613,200.18 in 2021[123] - The revenue from diagnostic services reached ¥12,674,242,036.95, accounting for 62.49% of total revenue, with a growth of 91.46% compared to ¥6,619,625,202.23 in the previous year[123] - The company achieved a revenue of ¥12,233,559,013.13 from the service sector, which constituted 60.32% of total revenue, marking a significant increase of 97.06% from ¥6,208,181,325.20 in 2021[123] Operational Expansion - The company established an overseas international headquarters in Singapore and expanded its product sales to 9 countries and regions, enhancing brand recognition globally[1] - The company has a nationwide distribution network covering 16 provinces and cities, with over 4,000 end customers[23] - The company aims to replicate its national-level precision center model across the country, enhancing operational capabilities[2] - The company has established a nationwide service network with 1 headquarters laboratory, 4 regional center laboratories, 35 provincial laboratories, 43 precision center laboratories, and 650 cooperative laboratories[55] - The company plans to accelerate business expansion in the Guangdong-Hong Kong-Macao Greater Bay Area, enhancing its regional presence[55] - The company has established new subsidiaries in Guangzhou and Hunan in 2022, expanding its market presence[93][94] - The company established Shanghai Dipu Kang Medical Testing Laboratory Co., Ltd. in July 2022, which has been included in the consolidated scope since then[73] - The company completed the deregistration of Xuancheng Dian Medical Testing Laboratory Co., Ltd. in September 2022, which is no longer included in the consolidated scope[74] - The company invested in the establishment of Kailai Pu (Suzhou) Biotechnology Co., Ltd. in September 2022, which has been included in the consolidated scope since then[74] - The company gained control over Hangzhou Yiyuan Investment Partnership (Limited Partnership) in December 2022, which has been included in the consolidated scope[75] Research and Development - The company’s R&D investment significantly increased, reflecting a growing focus on innovation and product development[49] - Research and development expenses rose to ¥638,473,629.58 in 2022, a 50.32% increase from ¥424,748,904.94 in 2021, indicating increased investment in R&D[89] - R&D investment in 2022 amounted to approximately ¥640.87 million, representing 3.16% of operating revenue, a slight decrease from 3.25% in 2021[98] - The number of R&D personnel increased by 4.48% to 956 in 2022, while the proportion of R&D personnel to total staff decreased from 8.23% to 7.28%[98] - The company is developing a digital trading project to integrate business and financial systems, aiming to enhance compliance and risk control capabilities[97] - The company has completed the first phase of its data intelligence project, establishing a data quality management system and achieving consistency and accuracy in data across subsidiaries[97] - The company is working on a new project for the clinical application of molecular typing in osteoarthritis, with data analysis currently underway[97] - The company has a significant increase in the number of R&D personnel with master's degrees, rising by 61.05% to 153 in 2022[98] - The company is developing a neuroimmune auxiliary diagnosis and treatment system to provide epidemiological data for rare diseases, aiming to improve information exchange efficiency between doctors and patients[97] - The company registered new medical devices in 2022, including a nucleic acid detection kit for COVID-19, which is intended for in vitro qualitative detection of suspected cases[99] Financial Management - The total cash inflow from operating activities in 2022 was ¥17,733,130,133.33, an increase of 43.08% compared to ¥12,394,019,383.76 in 2021[85] - The net cash flow from operating activities for 2022 was ¥1,639,364,992.07, reflecting a 24.39% increase from ¥1,317,918,147.43 in 2021[85] - The total cash outflow from investment activities in 2022 was ¥2,046,150,921.99, a 100.55% increase from ¥1,020,270,423.44 in 2021, resulting in a net cash flow from investment activities of -¥1,072,433,922.76[85] - The total cash inflow from financing activities in 2022 was ¥6,654,361,523.42, up 28.45% from ¥5,180,421,624.40 in 2021[85] - The net increase in cash and cash equivalents for 2022 was ¥2,001,990,148.27, a significant increase of 327.80% compared to ¥467,972,228.76 in 2021[85] - The company reported a significant increase in financial expenses to ¥298,235,596.07, a 37.13% rise from ¥217,478,820.01 in 2021, primarily due to increased borrowing and exchange rate fluctuations[89] - The net cash flow from financing activities was ¥1,428,044,075.67, an increase of 560.67% compared to the previous year, primarily due to increased cash inflows from project loans and employee stock option exercises, along with a decrease in cash outflows for debt repayment[106] - As of the end of 2022, cash and cash equivalents amounted to ¥4,200,038,342.09, representing 19.95% of total assets, up from 14.04% at the beginning of the year[107] - Accounts receivable increased to ¥9,955,600,758.99, accounting for 47.28% of total assets, up from 40.32% at the beginning of the year, driven by expanded business scale and revenue growth[107] - Long-term borrowings rose to ¥2,968,290,000.00, representing 14.10% of total assets, an increase of 8.41% due to optimization of the capital structure and conversion of some short-term debt to long-term[107] Product Development and Innovation - The company has developed a pathology AI system that is now in use in several top-tier hospitals, showcasing its commitment to digital transformation in medical diagnostics[1] - The company has developed the first AI-based CNS inflammatory demyelinating disease database platform in China, enhancing operational efficiency through digital transformation[57] - The pathology AI platform has accumulated over 1 million multimodal data samples, improving departmental efficiency by over 40%[57] - The company launched several new diagnostic products, including the thyroid cancer gene detection product and the lung cancer gene mutation detection, enhancing its product portfolio[135] - The company has established a comprehensive product line for cervical cancer screening, including reagents, equipment, and AI-assisted diagnostic systems[138] - The company’s investment in R&D and innovation has led to the development of advanced technologies, including the DP-TOF time-of-flight nucleic acid mass spectrometer[137] - The company has initiated the establishment of new subsidiaries and partnerships, with no significant impact on overall operations and performance reported[173] Social Responsibility and Community Engagement - The company donated over 400 boxes of medical emergency supplies to support disaster-stricken areas, contributing to public health initiatives and enhancing its brand influence[142] - The company has actively engaged in social responsibility initiatives, receiving recognition from the Zhejiang Provincial Government with the "Zhejiang Charity Award"[142] - The company has built the largest DNA reunion database in Zhejiang Province, helping over 370 families reunite with lost relatives[142] Quality Management and Compliance - The company is focused on quality management, adhering to ISO 15189 standards, and has established an industry-leading quality management system[198] - The company has received 59 domestic and international certification and accreditation certificates, leading in the third-party independent laboratory sector[198] - The company has achieved a perfect score in various inter-laboratory quality assessments, demonstrating its capabilities in high-throughput sequencing and clinical report interpretation[198] Strategic Goals and Future Plans - The company is committed to a strategic goal of becoming a platform-based enterprise for integrated medical diagnostics, focusing on service and product integration to enhance core competitiveness and sustainable development[186] - The company plans to increase R&D investment, focusing on developing multiple top-tier technology platforms in molecular diagnostics, mass spectrometry, and AI applications in pathology[196] - The company aims to enhance customer satisfaction by advancing a three-pronged platform service model targeting C-end, doctor-end, and sales-end, alongside building a clinical big data management platform[182] - The company aims to establish overseas laboratory centers, starting with the Southeast Asian market, to expand its diagnostic services internationally[177] - The company is developing a digital transformation strategy based on four directions: digital organization, digital products, digital marketing, and digital delivery[176]